Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Association Between Childhood Obesity and Myopia: A Prospective Cohort Study

18 november 2026 uppdaterad av: Weina Liu, Southeast University, China

This prospective observational cohort study will examine the association between obesity and myopia in children and adolescents. Approximately 600 participants aged 6 to 18 years will be enrolled at the Fourth Affiliated Hospital of Nanjing Medical University, including 300 participants with obesity and 300 participants with a body mass index within the normal range.

Participants will not be assigned to any study intervention. The study will collect information from body measurements, body composition assessments, eye examinations, lifestyle questionnaires, follow-up assessments, and existing clinical records. The investigators will evaluate whether obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat, are associated with myopia, axial length, refractive status, and changes in these outcomes over time. Lifestyle factors such as outdoor activity, near work, screen use, sleep, and diet will also be considered.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This is a single-center, prospective, observational cohort study involving children and adolescents aged 6 to 18 years who attend the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Approximately 600 participants will be enrolled, including 300 participants with obesity and 300 participants with a body mass index within the normal range. Obesity will be defined according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018).

No randomization, masking, or study-related clinical intervention will be performed. At baseline, the study will collect anthropometric measurements, body composition data, ophthalmic examination results, and lifestyle questionnaire data. Planned follow-up assessments will be used to evaluate changes in refractive status, axial length, scleral thickness, and myopia progression.

The principal study outcomes include myopia status and changes in axial length, spherical equivalent refraction, scleral thickness, and myopia progression. The study will examine associations between these outcomes and obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat.

Information on age, sex, parental history of myopia, birth history, medical history, medication use, outdoor activity, near work, screen use, sleep, and diet will be collected as potential confounding factors. Existing clinical laboratory results obtained during routine medical care, including blood lipids, fasting blood glucose, fasting insulin, C-peptide, and glycated hemoglobin, may be included in exploratory analyses when available.

The study will not collect additional blood, stool, or other biological samples solely for research purposes and will not increase the frequency or volume of blood collection. If residual blood remaining after routine clinical testing is available and its use is permitted by the ethics approval and informed consent, it may be used for related laboratory measurements without additional blood collection. The absence of existing laboratory results or residual blood will not affect study eligibility.

Statistical analyses will include group comparisons, multivariable linear or logistic regression, and linear mixed-effects models for repeated follow-up measurements. Analyses will adjust for relevant demographic, familial, and lifestyle factors.

Studietyp

Observationell

Inskrivning (Beräknad)

600

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Jiangsu
      • Nanjing, Jiangsu, Kina
        • Rekrytering
        • The Fourth Affiliated Hospital of Nanjing Medical University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

6 år till 18 år (Barn, Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study population will consist of approximately 600 children and adolescents aged 6 to 18 years attending the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Potential participants will be identified through the pediatric outpatient system and referrals from outpatient physicians. Approximately 300 participants will be enrolled in the obesity cohort and 300 in the normal-BMI cohort according to WS/T 586-2018. Enrollment requires written informed consent from a legal guardian and assent from the child or adolescent, as applicable.

Beskrivning

Inclusion Criteria:

  • Aged 6 to 18 years and able to cooperate with anthropometric measurements, ophthalmic examinations, questionnaire assessments, and follow-up visits.
  • For the obesity cohort, body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018); for the normal-BMI cohort, body mass index is within the normal range.
  • Best-corrected visual acuity of at least 0.8 in both eyes, with no apparent strabismus, opacity of the refractive media, or ocular structural abnormality.
  • The participant and legal guardian understand the study, voluntarily sign the applicable informed consent and assent documents, and are expected to comply with study procedures.
  • Able to complete the questionnaires and planned follow-up assessments.

Exclusion Criteria:

  • An ocular disease that may affect visual acuity or measurement of refractive status, including cataract, glaucoma, fundus disease, apparent strabismus, or another ocular structural abnormality.
  • A severe systemic disease or neurodevelopmental disorder that prevents cooperation with study examinations or follow-up.
  • A secondary condition or factor that substantially affects growth, development, or assessment of body weight.
  • Recent receipt of a myopia-control intervention that may substantially affect the evaluation of myopia progression when complete information about the intervention cannot be obtained.
  • Poor anticipated adherence, inability to complete follow-up, or withdrawal of informed consent by the legal guardian.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Obesity Cohort

Approximately 300 children and adolescents aged 6 to 18 years whose body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

The program should emphasize the health consequences of obesity and evidence-based weight management strategies, including maintaining a balanced diet, controlling energy intake, increasing physical activity, reducing sedentary behavior and screen time, and ensuring adequate sleep. Instruction, individualized counseling, and family involvement should be incorporated to improve health awareness and self-management skills and facilitate the development of a healthy lifestyle.

Normal-BMI Cohort

Approximately 300 children and adolescents aged 6 to 18 years whose body mass index is within the normal range according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change From Baseline in Axial Length
Tidsram: Baseline and 24 months

Axial length will be measured in millimeters for each eye using the same non-contact optical biometer at baseline and follow-up. Change in axial length (ΔAL) will be calculated as the value at 24 months minus the baseline value. Positive values indicate axial elongation. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔAL will also be evaluated.

Baseline and 24 months
Change From Baseline in Spherical Equivalent Refractive Error
Tidsram: Baseline and 24 months

Spherical equivalent refractive error will be calculated for each eye as spherical power plus one-half of cylindrical power and expressed in diopters (D), based on cycloplegic autorefraction. Change in spherical equivalent refractive error (ΔSE) will be calculated as the value at 24 months minus the baseline value. A negative change indicates a myopic shift. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔSE will also be evaluated.

Baseline and 24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change From Baseline in Scleral Thickness
Tidsram: Baseline and 24 months

Scleral thickness will be measured in micrometers at the same predefined anatomical location using optical coherence tomography at baseline and follow-up. Change in scleral thickness (ΔST) will be calculated as the value at 24 months minus the baseline value. A negative change indicates scleral thinning. Changes will be compared between children and adolescents with obesity and those with normal weight.

Baseline and 24 months
Change From Baseline in Regional Choroidal Thickness at 24 Months
Tidsram: Baseline and 24 months

Intraocular pressure, corneal curvature radius, mean keratometry, central corneal thickness, and anterior chamber depth will be measured in both eyes using the same standardized ophthalmic instruments at baseline and at the 24-month follow-up. Changes will be calculated as the 24-month value minus the corresponding baseline value. Intraocular pressure will be expressed in mmHg, corneal curvature radius and anterior chamber depth in millimeters, mean keratometry in diopters, and central corneal thickness in micrometers. Each parameter will be analyzed and reported separately.

Baseline and 24 months
Change From Baseline in Regional Retinal Thickness at 24 Months
Tidsram: Baseline and 24 months

Retinal thickness will be measured in micrometers at predefined temporal, central foveal, and nasal locations in both eyes using optical coherence tomography. Change at each location will be calculated as the value at 24 months minus the corresponding baseline value. Measurements from the temporal, central foveal, and nasal locations will be analyzed and reported separately.

Baseline and 24 months
Change From Baseline in Fasting Lipid Profile at 24 Months
Tidsram: Baseline and 24 months

Fasting lipid profile will include total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, all expressed in mmol/L. Laboratory results obtained during routine clinical care will be collected at baseline and at 24 months when available. Change in each lipid parameter will be calculated as the 24-month value minus the corresponding baseline value. Each lipid parameter will be analyzed and reported separately. No additional blood sampling will be performed solely for this study.

Baseline and 24 months
Body Fat Percentage
Tidsram: Baseline and 24 months

Body fat percentage will be estimated using bioelectrical impedance analysis and expressed as a percentage of total body mass.

Baseline and 24 months
Body Fat Mass
Tidsram: Baseline and 24 months

Fat mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

Baseline and 24 months
Body Muscle Mass
Tidsram: Baseline and 24 months

Muscle mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

Baseline and 24 months
Total Body Water
Tidsram: Baseline and 24 months

Total body water will be estimated using bioelectrical impedance analysis and expressed in liters (L).

Baseline and 24 months
Change From Baseline in Fasting Plasma Glucose at 24 Months
Tidsram: Baseline and 24 months

Change in fasting plasma glucose will be calculated as the 24-month value minus the baseline value and expressed in mmol/L.

Baseline and 24 months
Change From Baseline in Fasting Insulin at 24 Months
Tidsram: Baseline and 24 months

Change in fasting insulin will be calculated as the 24-month value minus the baseline value and expressed in µIU/mL.

Baseline and 24 months
Change From Baseline in C-Peptide at 24 Months
Tidsram: Baseline and 24 months

Change in C-peptide concentration will be calculated as the 24-month value minus the baseline value and expressed in pmol/L.

Baseline and 24 months
Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Months
Tidsram: Baseline and 24 months

Change in hemoglobin A1c (HbA1c) will be calculated by subtracting the baseline HbA1c percentage from the 24-month HbA1c percentage. The change will be expressed in percentage points.

Baseline and 24 months
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at 24 Months
Tidsram: Baseline and 24 months

At each visit, HOMA-IR will be calculated as fasting plasma glucose (mmol/L) multiplied by fasting insulin (µIU/mL), divided by 22.5, when both measurements are available from the same visit. Change will be calculated as the 24-month HOMA-IR value minus the baseline HOMA-IR value. HOMA-IR is a unitless index.

Baseline and 24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 juli 2025

Primärt slutförande (Beräknad)

1 juli 2027

Avslutad studie (Beräknad)

1 juli 2027

Studieregistreringsdatum

Först inskickad

14 november 2026

Först inskickad som uppfyllde QC-kriterierna

18 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 november 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera